19th Jul 2016 09:29
LONDON (Alliance News) - Food and farming industry technology and services company Benchmark Holdings PLC on Tuesday said it has released a new seabass vaccine to market for commercial field trials.
The vaccine aims to control Nodavirus, a disease which impedes seabass growth and causes high losses for producers. Benchmark noted the virus also effects turbot, barramundi and grouper fish and it will seek to provide products to cover those segments too.
"This is another key milestone for Benchmark and is testament to our increased capability, as we continue to invest in our manufacturing capacity and technology, to open up new markets for the company by solving major challenges for our customers," said Benchmark Chief Executive Malcolm Pye.
Benchmark shares were up 2.5% to 62.50 pence Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Benchmark Holdings